ARCUTIS BIOTHERAPEUTICS INC. - COMMON STOCK

Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update

14 مايو 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology

13 مايو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 مايو 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

29 أبريل 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Appoints David Topper as Chief Financial Officer

10 أبريل 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 أبريل 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference

28 مارس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Promotes Todd Tucker to Chief Human Resources Officer

11 مارس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting

10 مارس 2024 16:00:00 بحسب Nasdaq GlobeNewswire

New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction

09 مارس 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 مارس 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

04 مارس 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting

04 مارس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Arcutis to Present at the TD Cowen 44th Annual Health Care Conference

29 فبراير 2024 17:00:33 بحسب Nasdaq GlobeNewswire

Arcutis Announces Pricing of $150 Million Public Offering

28 فبراير 2024 23:30:21 بحسب Nasdaq GlobeNewswire

Arcutis Announces Proposed Public Offering

28 فبراير 2024 16:10:00 بحسب Nasdaq GlobeNewswire

Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan

28 فبراير 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

27 فبراير 2024 05:50:12 بحسب Nasdaq GlobeNewswire

Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results

16 فبراير 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 فبراير 2024 16:00:00 بحسب Nasdaq GlobeNewswire